刘瑞芳 副研究员
硕士招生类型：
硕士招生专业：
博士招生类型：
博士招生专业：
所在院系：附属东方医院
联系方式：liuruifang02@126.com
课题组链接：
研究方向
主要任职
科研业绩

前列腺癌耐药原因和肿瘤转移的分子机制
Molecularmechanism of prostate cancer development and drug resistance.




科研项目：
1. 国家自然科学基金面上项目，批准号：**，MEG3基因敲除对小鼠前列腺正常功能的影响和与前列腺癌转移的机制研究，2018/01－2021/12，53万元，负责人：刘瑞芳（已批准）
2. 国家自然科学基金青年基金项目，批准号**，miR-199a-3p靶向CD44+干/祖细胞对前列腺癌发生和转移的抑制作用研究，2014/01－2016/12，23万元，负责人：刘瑞芳（已结题）
3. 上海市自然科学基金青年项目，批准号：13ZR**，miR-199a-3p对CD44+前列腺癌干/祖细胞的调控作用及其对前列腺癌治疗效果的初步研究，2013/10－2016/09，10万元，负责人：刘瑞芳 （已结题）
4. 同济大学青年优秀人才培养行动计划，2012KJ041，Hsa-miR-199a-3p对前列腺癌干/祖细胞CD44阳性细胞的作用，2013/01－2014/12，2.5万元，负责人：刘瑞芳（已结题）

发表文章：
1. B.Xu*, R.F. Liu*, D.X. Zhang, B.G. Liu, K. Racaj, H.P. Chao, X.N. Zhang,T.C. Davis, J.S. Kirk, M. Chen, D.G. Tang. LncRNA MEG3 functions as atumor-suppressor in prostate cancer. (Eur. Urol, to be submitted) (*Co-firstauthors)
2. C.Liu*, R.F. Liu*, Q. Deng, B.G. Liu, H.P. Chao, K. Rycaj, Y. Takata, K.Lin, Y. Lu, Y. Zhong, J. Krolewski, J.J. Shen, D.G. Tang. MicroRNA-141suppresses prostate cancer stem cells and metastasis by targeting a cohort ofpro-metastasis genes including CD44, Pho GTPases, and EZH2. Nat. Commun. 2017Jan 23;8:14270. (*Co-first authors)
3. R.F.Liu,C. Liu, D.X. Zhang, B.G. Liu, X. Chen, K. Rycaj, C. Jeter, T.C. Davis, Y.D. Li,J.C. Wang, D.G. Tang. MicroRNA miR-199a-3p exhibits tumor-suppressive functionsin prostate cancer via targeting CD44, c-Myc, cyclin D1 and EGFR. Oncotarget.2016;7:56628-42.
4. X.Chen, Q.H. Li, X. Liu, C. Liu, R.F. Liu, K. Rycaj, D.X. Zhang, B.G. Liu,C. Jeter, T.C. Davis, K. Lin, Y. Lu, H.P. Chao, J.J. Shen, D.G. Tang. Defininga population of stem-like human prostate cancer cells that can generate andpropagate castration-resistant prostate cancer. Clin Cancer Res.2016;22:4505-16.
5. M.Jin, T. Zhang, C. Liu, M. A. Badeaux, B. Liu, R. Liu, C. Jeter, X. Chen,A. V. Vlassov, and D. G. Tang, Microrna-128 suppresses prostate cancer byinhibiting Bmi-1 to inhibit tumor-initiating cells. Cancer Res.2014;74:4183-95.
6. R.F.Liu,X. Xu, J. Huang, Q.L. Fei, F. Chen, Y.D. Li, Z.G. Han, Down-regulation ofmiR-517a and miR-517c promotes proliferation of hepatocellular carcinoma cellsvia targeting Pyk2. Cancer Lett. 2013;329:164-73.
7. Y.Li, B. Zhou, J. Dai, R. Liu, Z.G. Han, Aberrant upregulation of LRRC1contributes to human hepatocellular carcinoma. Mol Biol Rep. 2013;40:4543-51.
8. J.Huang, Q. Deng, Q. Wang, K.Y. Li, J.H. Dai, N. Li, Z.D. Zhu, B. Zhou, X.Y. Liu,R.F. Liu, Q.L. Fei, H. Chen, B. Cai, B. Zhou, H.S. Xiao, L.X. Qin, Z.G.Han, Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma.Nat Genet. 2012;44:1117-21.
9. X.Xu, R.F. Liu, X. Zhang, L.Y. Huang, F. Chen, Q.L. Fei, Z.G. Han, DLK1 asa potential target against cancer stem/progenitor cells of hepatocellularcarcinoma. Mol Cancer Ther. 2012;11:629-38.
X. Xu*, R.F. Liu*, B.B. Wan, W.M. Xing,J. Huang, Z.G. Han, Expression of a novel gene FAM43B repressing cellproliferation is regulated by DNA methylation in hepatocellular carcinoma celllines. Mol Cell Biochem. 2011;354:11-20. (*Co-first authors)